Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xu Qian has a total of 145 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Eberhard Albers

    Department of Otorhinolaryngology, Head and Neck Surgery, Berlin Institute of Health, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, 12200, Germany

    6 shared publications
  • Haoru Dong

    Department of Clinical Laboratory, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), The Chinese Academy of Sciences, Hangzhou, P. R. China

    5 shared publications
  • Andreas M. Kaufmann

    Clinic for Gynecology, Berlin Institute of Health, Charité‐Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt‐Universität zu Berlin Berlin Germany

    4 shared publications
  • Qiang Xu

    Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China

    4 shared publications
  • Andreas E. Albers

    Department of Clinical Medicine Oto‐Rhino‐Laryngology, Medical School Berlin Berlin Germany

    3 shared publications
  • Andreas Martin Kaufmann

    Department of Gynecology, HPV Research Laboratory, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    3 shared publications

Latest Publications

  • Open Access

    Harmonization and standardization of tumor markers and liquid biopsies in China: A short perspective

    by Linmei Zhong, Yi Yao, Xu Qian

    Circulating tumor markers such as serum carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and carbohydrate antigen (CA) 15-3 are widely used. In recent years, liquid biopsies, including circulating tumor DNA and tumor mutational burden, have been developed. In this review, we describe the status of harmonization and standardization of tumor markers in clinical practice in China, based on a systematic literature search of the CNKI and PubMed databases. Substantial inter-laboratory variability in measurement results persists. Participation in national external quality assessment (EQA) schemes and proficiency testing (PT) has successfully mitigated result discrepancies across different instruments and laboratory procedures during the last decades. Further development and refinement of standardization and harmonization approaches for liquid biopsies remain an unmet need.

  • MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

    by Peixiang Zheng, Yanni Lin, Meiyin Zhang, Zhiyuan Tang, Wenxing Qin, Min Xiao, Xue Sun, Yuli Shen, Zhiqiang Hu, Shuo Ru, et al.

    Limited efficacy of neoadjuvant chemotherapy (NAC) in pancreatic ductal adenocarcinoma (PDAC) underscores the need for novel combination strategies and a deeper understanding of metabolic determinants of chemoresistance. Here we identify methylmalonate semialdehyde dehydrogenase (MMSDH), a valine catabolism enzyme, as a driver of gemcitabine (GC) resistance. Hypoxia induces GCN5-mediated lactylation of MMSDH at K113. Lactylated MMSDH interacts with acyl-CoA synthetase long-chain family member 4 (ACSL4), generating propionyl-CoA to facilitate KAT8-mediated ACSL4 K606 propionylation. This modification enhances ACSL4–HSC70 binding, promoting its degradation through chaperone-mediated autophagy. Critically, this MMSDH-mediated ACSL4 propionylation correlates with low ACSL4 levels and poor NAC response in recipients. Combining dietary valine restriction with GC synergistically induces ferroptosis and suppresses tumor growth. Blocking MMSDH-K113la disrupts this axis, potentiating GC-induced ferroptosis and inhibiting tumor progression. These findings reveal a previously unknown mechanism of ferroptosis evasion through valine metabolism and ACSL4 regulation, nominating the GCN5–MMSDH–ACSL4 axis as a therapeutic target to enhance PDAC chemosensitivity.


  • Open Access

    Overexpression of TPM4 promotes cancer progression through EMT in anaplastic thyroid cancer

    by Hangjie Ying, Yahui Zhou, Xiaoming Jiang, Wei Cui, Shanshan Chen, Xiaofang Yao, Jianguo Feng, Dong Guo, Xu Qian

    Anaplastic thyroid cancer (ATC) is an undifferentiated tumour originating from thyroid follicular epithelium and represents the most malignant subtype of thyroid cancer. However, the mechanisms underlying ATC development are not fully understood. This study aimed to investigate the mechanisms driving ATC invasion and metastasis to provide novel insights into its aggressive behavior. Through an integrated bioinformatics analysis of the GEO database, we identified Tropomyosin 4 (TPM4) as a differentially expressed gene in ATC. Bioinformatic correlation and pathway enrichment analyses suggested that TPM4 expression is potentially linked to tumor cell invasion and lymph node metastasis. We showed that TPM4 was highly expressed in both ATC tissues and cell lines, and its expression levels were positively correlated with enhanced cell migration and invasion. Mechanistic studies indicated that TPM4 likely enhances tumour cell migration and invasion by facilitating cytoskeletal remodeling and promoting the epithelial-mesenchymal transition (EMT). Our findings suggest that TPM4 represents a promising diagnostic and therapeutic biomarker for ATC.

  • Screening of short-chain IRES elements for enhanced circRNA translation efficiency

    by Yulong Tang, Yuji Niu, Wenxi Wang, Beibei Wu, Jianmin Jiang, Xu Qian, Yu Zhang, Sitao Xie, Weihong Tan


  • Bispecific Aptamer-Drug Conjugates Selectively Eliminate Malignant Hematologic Cells for Treating Acute Myeloid Leukemia

    by Xiaodong Li, Jiacheng Dai, Yuenan Shi, Jie Chen, Fang Zhou, Xu Qian, Peng Wang, Xiaoyi Fu, Weihong Tan

    Surface antigen-directed immunotherapy is a curative treatment modality for acute myeloid leukemia (AML) that is characterized by the abundance and stability expression of surface antigens. However, current surface antigen-directed immunotherapies have shown poor outcomes and undesirable mortality rates in treating AML patients, primarily due to acquired resistance that arises from using single-target therapies to address the heterogeneous expression of surface antigens. Hence, in order to improve the efficacy of antigen-specific therapies for treating AML, we designed a bispecific aptamer-drug conjugate. In particular, cell-SELEX incorporating cell lysate-SELEX for aptamers with HEL cells yielded AptCD117, which specifically binds to CD117 (a highly expressed marker on both hematopoietic stem cells and primary AML cells) and has excellent performance in targeting human AML cells. Combined with CD71-binding aptamer LXD-11b (another broadly expressed surface antigen on leukemia cells), bispecific aptamers were designed to couple with monomethyl auristatin F (MMAF) for fabricating aptamer-drug conjugates. Results demonstrated that bispecific aptamer-MMAF conjugates efficiently kill different CD117 and CD71 expression levels of target AML cell lines in vitro. Importantly, the exposure of AML marrow specimens to bispecific aptamer-MMAF conjugates resulted in the selective elimination of primary AML cells in vitro and had no effect on healthy lymphocytes within the same specimens. Thus, these results provide a proof of concept for the generation of bispecific aptamer-drug conjugates directed against human AML cells, which hold the promise of advancing treatment strategies and improving AML patient outcomes.


  • Open Access

    CRISPR for companion diagnostics in low-resource settings

    by Xu Qian, Qiang Xu, Christopher J. Lyon, Tony Y. Hu

    New point-of-care tests (POCTs), which are especially useful in low-resource settings, are needed to expand screening capacity for diseases that cause significant mortality: tuberculosis, multiple cancers, and emerging infectious diseases.


  • Open Access

    Causal associations between thyroid cancer and IgA nephropathy: a Mendelian randomization study

    by Ziwei Mei, Fuhao Li, Ruizhen Chen, Zilong Xiao, Dongsheng Cai, Lie Jin, Xu Qian, Yucheng Wang, Jun Chen

    Background: The incidence of kidney disease caused by thyroid cancer is rising worldwide. Observational studies cannot recognize whether thyroid cancer is independently associated with kidney disease. We performed the Mendelian randomization (MR) approach to genetically investigate the causality of thyroid cancer on immunoglobulin A nephropathy (IgAN). Methods and results: We explored the causal effect of thyroid cancer on IgAN by MR analysis. Fifty-two genetic loci and single nucleotide polymorphisms were related to thyroid cancer. The primary approach in this MR analysis was the inverse variance weighted (IVW) method, and MR‒Egger was the secondary method. Weighted mode and penalized weighted median were used to analyze the sensitivity. In this study, the random-effect IVW models showed the causal impact of genetically predicted thyroid cancer across the IgAN risk (OR, 1.191; 95% CI, 1.131–1.253, P < 0.001). Similar results were also obtained in the weighted mode method (OR, 1.048; 95% CI, 0.980–1.120, P = 0.179) and penalized weighted median (OR, 1.185; 95% CI, 1.110–1.264, P < 0.001). However, the MR‒Egger method revealed that thyroid cancer decreased the risk of IgAN, but this difference was not significant (OR, 0.948; 95% CI, 0.855–1.051, P = 0.316). The leave-one-out sensitivity analysis did not reveal the driving influence of any individual SNP on the association between thyroid cancer and IgAN. Conclusion: The IVW model indicated a significant causality of thyroid cancer with IgAN. However, MR‒Egger had a point estimation in the opposite direction. According to the MR principle, the evidence of this study did not support a stable significant causal association between thyroid cancer and IgAN. The results still need to be confirmed by future studies.


  • Open Access

    Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer

    by Guochao Ye, Xiaomei Zhang, Mansheng Li, Zixiang Lin, Yongcan Xu, Haoru Dong, Jie Zhou, Jiaqi Zhang, Sheng Wang, Yunping Zhu, et al.

    Papillary thyroid cancer (PTC) is the most frequent subtype of thyroid cancer, but 20% of cases are indeterminate (i.e., cannot be accurately diagnosed) based on preoperative cytology, which might lead to surgical removal of a normal thyroid gland. To address this concern, we performed an in-depth analysis of the serum proteomes of 26 PTC patients and 23 healthy controls using antibody microarrays and data-independent acquisition mass spectrometry (DIA-MS). We identified a total of 1091 serum proteins spanning 10–12 orders of magnitude. 166 differentially expressed proteins were identified that participate in complement activation, coagulation cascades, and platelet degranulation pathways. Furthermore, the analysis of serum proteomes before and after surgery indicated that the expression of proteins such as lactate dehydrogenase A and olfactory receptor family 52 subfamily B member 4, which participate in fibrin clot formation and extracellular matrix-receptor interaction pathways, were changed. Further analysis of the proteomes of PTC and neighboring tissues revealed integrin-mediated pathways with possible crosstalk between the tissue and circulating compartments. Among these cross-talk proteins, circulating fibronectin 1 (FN1), gelsolin (GSN) and UDP-glucose 4-epimerase (GALE) were indicated as promising biomarkers for PTC identification and validated in an independent cohort. In differentiating between patients with benign nodules or PTC, FN1 produced the best ELISA result (sensitivity = 96.89%, specificity = 91.67%). Overall, our results present proteomic landscapes of PTC before and after surgery as well as the crosstalk between tissue and the circulatory system, which is valuable to understand PTC pathology and improve PTC diagnostics in the future.


  • Open Access

    Integration and viral oncogene expression of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma and gastric cancer

    by Qiang Xu, Haoru Dong, Zhiyu Wang, Pei Zhang, Andreas E. Albers, Andreas M. Kaufmann, Zhi‐Ming Zheng, Xu Qian

    Persistent high‐risk human papillomavirus (HR‐HPV) infections cause cervical cancer and a fraction of head and neck cancer. To investigate whether HR‐HPV infection might be also involved in the development of gastric cancer (GC), we developed a platform utilizing a rolling circle amplification (RCA)‐based nested L1 polymerase chain reaction with Sanger sequencing to genotype the HPV DNA in cancer tissues of 361 GC and 89 oropharyngeal squamous cell carcinomas (OPSCC). HPV transcriptional activity was determined by E6/E7 mRNA expression and a 3’ rapid amplification of cDNA ends was performed to identify HPV integration and expression of virus−host fusion transcripts. Ten of 361 GC, 2 of 89 OPSCC, and 1 of 22 normal adjacent tissues were HPV L1 DNA‐positive. Five of the 10 HPV‐positive GC were genotyped as HPV16 by sequencing and 1 of 2 GC with RCA/nested HPV16 E6/E7 DNA detection exhibited HPV16 E6/E7 mRNA. Two OPSCC displayed HPV16 L1 DNA and E6/E7 mRNA, of which 1 OPSCC tissue showed virus−host RNA fusion transcripts from an intron region of KIAA0825 gene. Together, our data reveal viral oncogene expression and/or integration in GC and OPSCC and a possible etiology role of HPV infections in gastric carcinogenesis.


  • Top Cited Papers

    Aptamer-Based Targeted Protein Degradation

    by Yuan Liu, Xu Qian, Chunyan Ran, Longjie Li, Ting Fu, Dan Su, Sitao Xie, Weihong Tan

    The selective removal of misfolded, aggregated, or aberrantly overexpressed protein plays an essential role in maintaining protein-dominated biological processes. In parallel, the precise knockout of abnormal proteins is inseparable from the accurate identification of proteins within complex environments. Guided by these precepts, small molecules, or antibodies, are commonly used as protein recognition tools for developing targeted protein degradation (TPD) technology. Indeed, TPD has shown tremendous prospects in chronic diseases, rare diseases, cancer research, and other fields. Meanwhile, aptamers are short RNA or DNA oligonucleotides that can bind to target proteins with high specificity and strong affinity. Accordingly, aptamers are actively used in designing and constructing TPD technology. In this perspective, we provide a brief introduction to TPD technology in its current progress, and we summarize its application challenges. Recent advances in aptamer-based TPD technology are reviewed, together with corresponding challenges and outlooks.